Centessa Pharmaceuticals (CNTA) News Today $12.00 -1.57 (-11.60%) Closing price 03:59 PM EasternExtended Trading$12.01 +0.01 (+0.12%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Avidity Partners Management LP Sells 966,200 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Avidity Partners Management LP decreased its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 45.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,165,800 shares of tMay 6 at 7:39 AM | marketbeat.comIs Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5 at 8:07 AM | insidermonkey.comAnalysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Price Target at $27.71May 5 at 1:35 AM | americanbankingnews.comAllostery Investments LP Makes New Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Allostery Investments LP acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 284,517 shares of the company's stock, valued at approximateMay 4 at 7:45 AM | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by Ally Bridge Group NY LLCAlly Bridge Group NY LLC cut its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 21.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 244,538 shares of the company's stock afterMay 4 at 7:45 AM | marketbeat.com5AM Venture Management LLC Cuts Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)5AM Venture Management LLC cut its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 35.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 830,945 shares of the company's stock aMay 4 at 7:15 AM | marketbeat.comSchonfeld Strategic Advisors LLC Acquires Shares of 365,200 Centessa Pharmaceuticals plc (NASDAQ:CNTA)Schonfeld Strategic Advisors LLC bought a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 365,200 shares of the company's stock, valued at approximately $6,117,000.May 4 at 5:06 AM | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Recommendation of "Buy" by BrokeragesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among anMay 4 at 2:43 AM | marketbeat.comBoothbay Fund Management LLC Invests $702,000 in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Boothbay Fund Management LLC purchased a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 41,900 shares of the company's stock, valued atMay 2, 2025 | marketbeat.comFirst Light Asset Management LLC Sells 134,948 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)First Light Asset Management LLC trimmed its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,805,184 shares of the company's stock after selling 134,948 sharApril 30, 2025 | marketbeat.com1,253,379 Shares in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Acquired by Foresite Capital Management VI LLCForesite Capital Management VI LLC bought a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,253,379 shares of the company's stock, valued at approximately $20,994,April 30, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Acquired by Lord Abbett & CO. LLCLord Abbett & CO. LLC lifted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 63.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 440,495 shares of the company's stock after purcApril 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Raises Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Price T Rowe Associates Inc. MD increased its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 14.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,364,392 shares of the company's stock after acquiring an additional 685,3April 30, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 2,080 SharesApril 30, 2025 | insidertrades.comMarshall Wace LLP Lowers Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Marshall Wace LLP reduced its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 22.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 139,732 shares of the company's stock after selling 41,121 shares during the periodApril 29, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Reduces Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)T. Rowe Price Investment Management Inc. lowered its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,418,600 shares of the coApril 28, 2025 | marketbeat.comLegal & General Group Plc Buys Shares of 75,451 Centessa Pharmaceuticals plc (NASDAQ:CNTA)Legal & General Group Plc purchased a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 75,451 shares of the company's stocApril 28, 2025 | marketbeat.comJump Financial LLC Sells 23,411 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Jump Financial LLC cut its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 47.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,700 shares of the company's stock after selApril 27, 2025 | marketbeat.comBlue Owl Capital Holdings LP Decreases Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Blue Owl Capital Holdings LP cut its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 13.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 220,000 shares of the companApril 26, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Bought by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. increased its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 22.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,119,027 shares of the company's stock after buyinApril 26, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 11,742 SharesApril 26, 2025 | insidertrades.comRenaissance Technologies LLC Has $2.99 Million Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Renaissance Technologies LLC trimmed its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 14.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 178,600 shares of the company's sApril 26, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 14,656 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 14,656 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $12.29, for a total transaction of $180,122.24. Following the completion of the sale, the chief executive officer now directly owns 261,361 shares in the company, valued at approximately $3,212,126.69. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.April 24, 2025 | marketbeat.comSilverarc Capital Management LLC Has $10.03 Million Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Silverarc Capital Management LLC reduced its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 19.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 598,952 shares of the company's stocApril 24, 2025 | marketbeat.comDiadema Partners LP Makes New $2.21 Million Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Diadema Partners LP acquired a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 131,862 shares ofApril 24, 2025 | marketbeat.comSaurabh Saha Sells 14,656 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockApril 23, 2025 | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Holdings Lifted by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 40.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,385 shares of the company's stApril 23, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 130,312 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Affinity Asset Advisors LLC grew its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 13.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,095,924 shares of the company's stock after acquiring an additional 130,312 shares dApril 17, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 6.5% - Time to Sell?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 6.5% - Here's What HappenedApril 11, 2025 | marketbeat.comADAR1 Capital Management LLC Has $2.58 Million Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)ADAR1 Capital Management LLC lifted its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 561.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 154,027 shares of the company's stock aApril 9, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Rating of "Buy" from BrokeragesShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have received a consensus rating of "Buy" from the eight brokerages that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 montApril 8, 2025 | marketbeat.comTrexquant Investment LP Buys 90,233 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Trexquant Investment LP raised its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 52.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 261,184 shares of the company's stock after purchasing an additional 90,233 shares during theApril 7, 2025 | marketbeat.comRelative Strength Alert For Centessa PharmaceuticalsApril 3, 2025 | nasdaq.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 5% - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5% - Here's WhyApril 3, 2025 | marketbeat.comMorgan Stanley Remains a Buy on Centessa Pharmaceuticals (CNTA)April 2, 2025 | markets.businessinsider.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by American Century Companies Inc.American Century Companies Inc. lessened its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 5.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,079,708 shares of the companApril 2, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Piper SandlerPiper Sandler assumed coverage on Centessa Pharmaceuticals in a report on Monday. They set an "overweight" rating and a $38.00 price target for the company.April 1, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Overweight RecommendationMarch 31, 2025 | msn.comB. Riley Issues Negative Estimate for CNTA EarningsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - B. Riley decreased their Q1 2025 earnings per share (EPS) estimates for shares of Centessa Pharmaceuticals in a research note issued to investors on Thursday, March 27th. B. Riley analyst M. Mamtani now forecasts that the company will posMarch 31, 2025 | marketbeat.comAnalysts Offer Predictions for CNTA Q3 EarningsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Centessa Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger forecasts that the compMarch 28, 2025 | marketbeat.comNotable Two Hundred Day Moving Average Cross - CNTAMarch 28, 2025 | nasdaq.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $163,400.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the sale, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.March 27, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's What HappenedMarch 27, 2025 | marketbeat.comCentessa Pharmaceuticals' (CNTA) "Buy" Rating Reaffirmed at GuggenheimGuggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday.March 27, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CNTA Q1 Earnings?Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a research note issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger expects that the company will earn ($0.37) per shareMarch 27, 2025 | marketbeat.comGregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMarch 27, 2025 | insidertrades.comCentessa reports Q4 EPS (84c), consensus (35c)March 25, 2025 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Releases Earnings ResultsCentessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.11.March 25, 2025 | marketbeat.comCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024March 24, 2025 | globenewswire.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the completion of the transaction, the chief executive officer now owns 276,017 shares in the company, valued at approximately $4,606,723.73. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.March 22, 2025 | marketbeat.com Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Media Mentions By Week CNTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTA News Sentiment▼1.020.69▲Average Medical News Sentiment CNTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTA Articles This Week▼175▲CNTA Articles Average Week Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LNTH News BBIO News TGTX News LEGN News SRPT News TLX News ADMA News BPMC News VRNA News NUVL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTA) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...Crypto 101 Media | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTA Stock Free CNTA Stock Alerts